MAJI Moves to Cancel Over 15M Shares As It Pushes Toward Commercialization

Checkers
Sep 4
3 min read

Glioblastoma is one of medicine's most formidable enemies. It's a brain cancer so aggressive that for decades, even the most advanced treatments have failed to stop it. The core of the problem is delivery: most drugs can't get past the brain's natural defenses, and the cancer stem cells that fuel the tumor's growth are notoriously resistant to attack.

But a biotech company, Exousia Pro (OTCID: $MAJI), has developed a technology that acts like a biological key, unlocking a new way to fight these tumors directly. Using a natural delivery system called exosomes, MAJI can package genetic therapies and send them straight to the source of the cancer. To turn this core science into a business, they have now

launched a multi-pronged commercial operation. This new structure includes three divisions: Exousia Ai for the core cancer research, Exousia Health for consumer wellness products, and Exousia Wholesale to supply other companies.

Bar graph showing the effect of Glioblastoma therapy with chemo and exosome. High TMZ concentration triples cell death. Text explains results.

In laboratory studies, treatment with the current FDA-approved drug temozolomide killed fewer than 25% of glioblastoma stem cells, while combining it with exosome-delivered therapy drove cell elimination close to 100%. In April, Exousia Pro announced completion of its preclinical trial in mice using patient-derived tumor cells, reporting that the therapy significantly enhanced elimination of cancer stem cells and is using the results of this study to bolster their FDA Orphan Drug Application.

This breakthrough addresses a massive market, currently valued at $8.7 billion and projected to grow to $18.5 billion over the next decade. To immediately tap into this space, a pending partnership will give MAJI's Health division access to 200,000 patients, creating an instant distribution channel and generating revenue to fund the long-term cancer research.

Securities details chart titled "MAJI Security Details" with market cap, authorized and outstanding shares, and DTC holdings, dated 2025.

While that commercial front expands, management is making an equally aggressive move to further clean up an already stellar share structure. The company has just over 40 million shares outstanding and only about 10 million unrestricted shares, and it is currently in a legal battle to cancel an additional 15.5 million shares tied to previous management. A win in the lawsuit, filed in June, would remove around 40% of the current outstanding shares.

The move to protect the share structure is huge, as exosome and advanced therapy deals are already attracting major transactions at premium valuations. Lonza acquired Roche’s Vacaville biologics site for next-generation biologics in a $1.2 billion deal, Jazz Pharmaceuticals licensed exosome programs from Codiak BioSciences in an agreement valued at up to $1 billion, and Lonza also acquired Codiak’s dedicated exosome manufacturing facility and technology platform in a transaction worth tens of millions. In stark contrast, MAJI is advancing its own validated science to commercialization with a market cap of just under $5 million in a market where specialized platforms are clear acquisition targets by major Big Pharma players.

MAJI is hitting on three critical fronts at once: validated science that addresses a desperate medical need, a business model with multiple ways to make money, and a share structure that could soon become much tighter. This combination puts the company in a powerful position as precision cancer therapy and the multi-billion dollar exosome market become the new standard of care.

Disclaimer: The content provided is for informational purposes only and does not constitute a comprehensive analysis of the mentioned topics. All views, opinions, and predictions are those of the author at the time of writing and may change. This should not be considered as investment advice or a solicitation to buy or sell any securities. Readers are strongly advised to review the company’s official disclosures, filings, and updates to ensure accurate and current information. Always conduct your own research or consult with a financial advisor before making investment decisions. The author and publisher are not liable for any losses or damages arising from the use of this information. Please remember that all investments carry risks, including potential loss of principal.